Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Tampa, Florida 33614


The primary purpose of this research study is to evaluate the safety and tolerability of raltegravir 400 mg taken twice a day compared to an NRTI (nucleotide reverse transcriptase inhibitor) backbone, each with a PI (protease inhibitor) boosted with ritonavir based medication regimen, in HIV-1 positive patients. NRTI and PI are two of the categories of medications currently being used to treat HIV.


Inclusion Criteria: - documented HIV RNA <75 copies/mL - no history of documented coronary artery disease - Subject with Hepatitis C co-infection may be enrolled provided the subjects are stable and meet all eligibility criteria. - no clinical evidence of active pulmonary disease - agrees to use an acceptable method of birth control throughout the study. Exclusion Criteria: - currently failing a boosted PI based regimen. - receiving a second line boosted PI regimen including boosted tipranavir or boosted darunavir. - chronic hepatitis B infection.



Primary Contact:

Principal Investigator
Cynthia A Mayer, DO
St Joseph's Comprehensive Research Institute

Backup Contact:


Location Contact:

Tampa, Florida 33614
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.